We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Offers Revised Guidance on Prior Approval Supplements Under GDUFA III
FDA Offers Revised Guidance on Prior Approval Supplements Under GDUFA III
In the wake of the reauthorization of the Generic Drug User Fee Amendments (GDUFA), the FDA has updated its guidance for prior approval supplements (PAS) and amendments for abbreviated new drug applications (ANDA) under GDUFA III.